Why Adobe Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Shares of Adobe Inc. (NASDAQ:ADBE) rose sharply in today’s pre-market trading following better-than-expected second-quarter earnings and strong guidance.…
Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session
Shares of Signet Jewelers Limited (NYSE:SIG) fell sharply during Thursday’s session following mixed first-quarter earnings including an 8.9%…
Why Broadcom Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Shares of Broadcom Inc. (NASDAQ:AVGO) rose sharply in today’s pre-market trading after the company posted stronger-than-expected results for…
PainReform CEO Ilan Hadar Discusses Latest Developments Related To PRF-110 To Help Tackle The Opioid Epidemic
PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates.
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Shares of Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced pricing of a $6 million public offering of shares at $0.14 per share.
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Shares of PriceSmart, Inc. (NASDAQ: PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for its second quarter.
EXCLUSIVE: PainReform’s Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions
PainReform reveals superior IVR rates of PRF-110 vs. competitors in post-surgical pain management. Findings showcase PRF-110's extended analgesic effect potential, reducing opiate dependency.
EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug
PainReform hits a 50% enrollment target in the Phase 3 trial for PRF-110 in bunionectomy. No serious adverse events were reported. Over 200 patients enrolled across 8 U.S. sites. CEO Ilan Hadar is optimistic about PRF-110's potential to revolutionize postoperative pain management.
Painreform Provides Business Update For Q3, As Of September 30, 2023, The Company Had Cash And Short-Term Deposits Of $8.6M
PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the third